&nbsp;

NewOHCCO logo

Jan 2020

Regimen

MTRX(HD)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Curative

Drugs Used:

methotrexate,

leucovorin

... Show more tags

Quick Link(s):

Regimen Monograph

Jun 2020

Guidelines and Advice

Minimal Residual Disease Testing in Acute Leukemia

Status: Current
ID: MOTAC-6
Version: 2

Sep 2020

Document

MucinousOvarianCancerTreatmentPathwayMap_2020-01.pdf

Mar 2020

Regimen

MPC+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

ODB - General Benefit

procarbazine

Drugs Used:

riTUXimab (Unfunded),

Quick Link(s):

Regimen Monograph

Dec 2020

Neuroendocrine Tumours (NETs)

Regimen

MFOLFOX6+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Manipulation sécuritaire des médicaments contre le cancer et des fluides corporels à la maison

Regimen

NIVL+IPIL(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

Drugs Used:

nivolumab,

ipilimumab

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2024

Document

metis-brochure-thumbnail.jpg

Apr 2021

Document

metis-fr-brochure-thumbnail.jpg

May 2021

Document